Filtered By:
Therapy: Antiviral Therapy

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 305 results found since Jan 2013.

Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up
Conclusion: In CLL, a neoplastic antigen-specific B-cell clone proliferates, and the progeny cells accumulate and outgrow other B cells, leading to immune deficiency. Considering the low humoral immune response and ineffective clearance of SARS-Cov-2 in CLL patients, the follow-up and home quarantine period should be extended. We need further studies to clarify suspending or continuing CLL therapy during COVID infection. For those patients who are prone to progression to severe disease, administering humoral immunity therapies can help to prevent disease progression and quickly meet the cure criteria.
Source: Frontiers in Oncology - July 2, 2020 Category: Cancer & Oncology Source Type: research

A case of coronavirus HKU1 encephalitis.
This study might help understand more about coronavirus and improve the awareness of pathogen detection in patients with coronavirus encephalitis. Keywords: coronavirus HKU1; encephalitis. PMID: 32551794 [PubMed - in process]
Source: Acta Virologica - June 20, 2020 Category: Infectious Diseases Authors: Cao P, Huang Y, Wu Z, Sun H, Ma W, Fang T Tags: Acta Virol Source Type: research

The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium
Publication date: Available online 19 June 2020Source: Antiviral ResearchAuthor(s): Yung Jin Jeon, Chan Hee Gil, Ara Jo, Jina Won, Sujin Kim, Hyun Jik Kim
Source: Antiviral Therapy - June 19, 2020 Category: Virology Source Type: research

Exportin 1 inhibition as antiviral therapy.
Abstract Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies ...
Source: Drug Discovery Today - June 18, 2020 Category: Drugs & Pharmacology Authors: Uddin MH, Zonder JA, Azmi AS Tags: Drug Discov Today Source Type: research

Challenge infection model for MERS-CoV based on naturally infected camels
Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus that infects humans and camels with no approved antiviral therapy or vaccine. Some vaccines are in development for camels as a one-h...
Source: Virology Journal - June 17, 2020 Category: Virology Authors: Naif Khalaf Alharbi, Osman H. Ibrahim, Ali Alhafufi, Samy Kasem, Ali Aldowerij, Raed Albrahim, Ali Abu-obaidah, Ali Alkarar, Faisal Altaib Bayoumi, Ali Mohammed Almansour, Musaad Aldubaib, Hail M. Al-Abdely, Hanan H. Balkhy and Ibrahim Qasim Tags: Research Source Type: research

The role of ophthalmology in the COVID-19 pandemic.
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 19 (COVID-19) has led to a worldwide pandemic. This pandemic presents a huge challenge for the healthcare system and also for ophthalmologists. Previous studies and case reports indicated that SARS-CoV‑2 also infects the conjunctiva resulting in conjunctivitis. In addition, infectious virus particles in the tear fluid can be potential sources of infection; however, the detection of SARS-CoV‑2 RNA in the tear fluid has rarely been successful. Although isolated conjunctival involvement is highly unlikely, at t...
Source: Der Ophthalmologe - June 8, 2020 Category: Opthalmology Authors: Rokohl AC, Loreck N, Wawer Matos PA, Mor JM, Zwingelberg S, Grajewski RS, Cursiefen C, Heindl LM Tags: Ophthalmologe Source Type: research

Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Authors: Sun J, Chen Y, Fan X, Wang X, Han Q, Liu Z Abstract Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work tog...
Source: Postgraduate Medicine - June 5, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies
COVID-19 is caused by SARS-CoV-2 which is a new enveloped virus that belongs to the Beta coronavirus genus. As a major health crisis, SARS-CoV-2 has infected over a million people around the world. There is currently no specific treatment available for patients with COVID-19 infection. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been used in clinical practice. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and discusses the clinical value of blood transfusi...
Source: Transfusion and Apheresis Science - June 2, 2020 Category: Hematology Authors: Ying Li, Shanglong Liu, Shuchao Zhang, Qiang Ju, Shaoqiang Zhang, Yuanming Yang, Haiyan Wang Tags: Review Source Type: research

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit
AbstractRemdesivir is one of the most promising drugs to treat COVID-19 based on the following facts: remdesivir has a broad-spectrum antiviral mechanism of action; it demonstratedin vitro activity against SARS-CoV-2 andin vivo efficacy in animal models against the similar coronavirus MERS-CoV; its safety profile has been tested in Ebola patients and in compassionate use in COVID-19 patients. Currently, remdesivir is being investigated in ten randomized controlled trials against COVID-19. The dose regimen of remdesivir is an IV loading dose of 200  mg on day 1 followed by daily IV maintenance doses of 100 mg for 5–9 d...
Source: The AAPS Journal - May 25, 2020 Category: Drugs & Pharmacology Source Type: research

Delayed Initiation of Remdesivir in a COVID ‐19‐Positive Patient
We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS ‐CoV‐2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40‐year‐old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID‐19) symptoms including dry cough, fever, and shortness of breath progressing to intub ation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID‐19 ...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 19, 2020 Category: Drugs & Pharmacology Authors: Emily Hillaker, Julie J. Belfer, Anamaria Bondici, Hani Murad, Lisa E. Dumkow Tags: Case Report Source Type: research

Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
Condition:   Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection) Intervention:   Other: convalescent plasma application to SARS-CoV-2 infected patients Sponsor:   University Hospital, Basel, Switzerland Recruiting
Source: ClinicalTrials.gov - May 15, 2020 Category: Research Source Type: clinical trials